← golden set
MRK
Merck & Co., Inc.Healthcareanswer key
| field | SEC value | XBRL concept | printed on |
|---|---|---|---|
| Total revenue | $65.0B | Revenues | Sales |
| Operating income | - | not reported | not in this filing's XBRL |
| Net income attributable to the company | $18.3B | NetIncomeLoss | Net Income Attributable to Merck & Co., Inc. |
| Diluted EPS | $7.28 | EarningsPerShareDiluted | Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders |
| Cash and cash equivalents | $14.6B | CashAndCashEquivalentsAtCarryingValue | Cash and cash equivalents |
| Total assets | $136.9B | Assets | (unlabeled total row) · (unlabeled total row) |
| Total liabilities | - | not reported | not in this filing's XBRL |
| Total shareholders' equity attributable to the company | $52.6B | StockholdersEquity | Total Merck & Co., Inc. stockholders’ equity |
| Net cash from operating activities | $16.5B | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by Operating Activities |
| Net cash from investing activities | -$13.7B | NetCashProvidedByUsedInInvestingActivities | Net Cash Used in Investing Activities |
| Net cash from financing activities | -$1.9B | NetCashProvidedByUsedInFinancingActivities | Net Cash Used in Financing Activities |
Income statement
table #43 · score 48.8 vs 26.3 runner-up · in millions| 2025 | 2024 | 2023 | |
| Sales | 65,011 | 64,168 | 60,115 |
| Costs, Expenses and Other | |||
| Cost of sales | 16,382 | 15,193 | 16,126 |
| Selling, general and administrative | 10,733 | 10,816 | 10,504 |
| Research and development | 15,789 | 17,938 | 30,531 |
| Restructuring costs | 889 | 309 | 599 |
| Other (income) expense, net | 151 | (24) | 466 |
| 43,944 | 44,232 | 58,226 | |
| Income Before Taxes | 21,067 | 19,936 | 1,889 |
| Taxes on Income | 2,804 | 2,803 | 1,512 |
| Net Income | 18,263 | 17,133 | 377 |
| Less: Net Income Attributable to Noncontrolling Interests | 9 | 16 | 12 |
| Net Income Attributable to Merck & Co., Inc. | 18,254 | 17,117 | 365 |
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | 7.30 | 6.76 | 0.14 |
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | 7.28 | 6.74 | 0.14 |
Balance sheet
table #45 · score 34.5 vs 10 runner-up · in millions| 2025 | 2024 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | 14,565 | 13,242 |
| Short-term investments | - | 447 |
| Accounts receivable (net of allowance for doubtful accounts of $97 in 2025 and $89 in 2024) | 11,775 | 10,278 |
| Inventories (excludes inventories of $5,681 in 2025 and $4,193 in 2024classified in Other assets - see Note 7) | 6,658 | 6,109 |
| Other current assets | 10,518 | 8,706 |
| Total current assets | 43,516 | 38,782 |
| Investments | 956 | 463 |
| Property, Plant and Equipment (at cost) | ||
| Land | 321 | 307 |
| Buildings | 17,983 | 16,360 |
| Machinery, equipment and office furnishings | 19,760 | 18,283 |
| Construction in progress | 9,166 | 7,984 |
| 47,230 | 42,934 | |
| Less: accumulated depreciation | 21,914 | 19,155 |
| 25,316 | 23,779 | |
| Goodwill | 21,579 | 21,668 |
| Other Intangibles, Net | 26,681 | 16,370 |
| Other Assets | 18,818 | 16,044 |
| 136,866 | 117,106 | |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | 2,589 | 2,649 |
| Trade accounts payable | 4,404 | 4,079 |
| Accrued and other current liabilities | 14,468 | 15,694 |
| Income taxes payable | 4,726 | 3,914 |
| Dividends payable | 2,140 | 2,084 |
| Total current liabilities | 28,327 | 28,420 |
| Long-Term Debt | 46,750 | 34,462 |
| Deferred Income Taxes | 1,439 | 1,387 |
| Other Noncurrent Liabilities | 7,688 | 6,465 |
| Merck & Co., Inc. Stockholders’ Equity | ||
| Common stock, $0.50 par valueAuthorized - 6,500,000,000 sharesIssued - 3,577,103,522 shares in 2025 and 2024 | 1,788 | 1,788 |
| Other paid-in capital | 45,029 | 44,704 |
| Retained earnings | 73,075 | 63,069 |
| Accumulated other comprehensive loss | (4,287) | (4,945) |
| 115,605 | 104,616 | |
| Less treasury stock, at cost: 1,102,476,756 shares in 2025 and 1,049,466,187 shares in 2024 | 62,999 | 58,303 |
| Total Merck & Co., Inc. stockholders’ equity | 52,606 | 46,313 |
| Noncontrolling Interests | 56 | 59 |
| Total equity | 52,662 | 46,372 |
| 136,866 | 117,106 |
Cash flow statement
table #47 · score 55 vs 10 runner-up · in millions| 2025 | 2024 | 2023 | |
| Cash Flows from Operating Activities | |||
| Net income | 18,263 | 17,133 | 377 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Amortization | 2,793 | 2,395 | 2,044 |
| Depreciation | 3,045 | 2,104 | 1,828 |
| Intangible asset impairment charges | 55 | 39 | 792 |
| Income from investments in equity securities, net | (368) | (14) | (340) |
| Charges for certain research and development asset acquisitions | - | 3,456 | 11,409 |
| Deferred income taxes | (1,671) | (1,249) | (1,899) |
| Share-based compensation | 820 | 761 | 645 |
| Other | 511 | 510 | 355 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (1,090) | (244) | (1,148) |
| Inventories | (1,180) | (835) | (816) |
| Trade accounts payable | 110 | 182 | (380) |
| Accrued and other current liabilities | (1,841) | (2,328) | 1,783 |
| Income taxes payable | 137 | 1,023 | 214 |
| Noncurrent liabilities | 195 | (49) | 456 |
| Other | (3,307) | (1,416) | (2,314) |
| Net Cash Provided by Operating Activities | 16,472 | 21,468 | 13,006 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (4,112) | (3,372) | (3,863) |
| Purchases of securities and other investments | (1,207) | (519) | (955) |
| Proceeds from sales of securities and other investments | 1,678 | 377 | 1,658 |
| Proceeds from sale of Seagen Inc. common stock | - | - | 1,145 |
| Acquisition of Verona Pharma plc, net of cash acquired | (10,042) | - | - |
| Acquisition of Eyebiotech Limited, net of cash acquired | - | (1,344) | - |
| Acquisition of Elanco Animal Health Incorporated aqua business | - | (1,303) | - |
| Acquisition of Harpoon Therapeutics, Inc., net of cash acquired | - | (746) | - |
| Acquisition of MK-1045 from Curon Pharmaceutical | - | (700) | - |
| Acquisition of Prometheus Biosciences, Inc., net of cash acquired | - | - | (10,705) |
| Acquisition of Imago BioSciences Inc., net of cash acquired | - | - | (1,327) |
| Other | (58) | (127) | (36) |
| Net Cash Used in Investing Activities | (13,741) | (7,734) | (14,083) |
| Cash Flows from Financing Activities | |||
| Payments on debt | (2,503) | (1,290) | (1,755) |
| Proceeds from issuance of debt | 13,880 | 3,599 | 5,939 |
| Purchases of treasury stock | (5,084) | (1,306) | (1,346) |
| Dividends paid to stockholders | (8,176) | (7,840) | (7,445) |
| Proceeds from exercise of stock options | 92 | 177 | 125 |
| Other | (131) | (372) | (328) |
| Net Cash Used in Financing Activities | (1,922) | (7,032) | (4,810) |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | 563 | (293) | 23 |
| Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 1,372 | 6,409 | (5,864) |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $76, $68 and $79 of restricted cash at January 1, 2025, 2024 and 2023, respectively, included in Other current assets) | 13,318 | 6,909 | 12,773 |
| Cash, Cash Equivalents and Restricted Cash at End of Year (includes $125, $76 and $68 of restricted cash at December 31, 2025, 2024 and 2023, respectively, included in Other current assets) | 14,690 | 13,318 | 6,909 |